Liposome-mediated therapy of human immunodeficiency virus type-1 and mycobacterium infections
Authors:
- 1 January 1995
- journal article
- research article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 5 (4) , 669-691
Abstract
We review our recent work on the use of liposomes for the delivery of antiviral agents to human immunodeficiency virus type-1 (HIV-1) infected cells, and antimycobactcrial drugs to cells harboring Mycobacterium avium complex or Mycobacterium tuberculosis. Soluble CD4 has been used to target liposomes to HIV-1-infected cells. Antisense oligodeoxynucleotides have been effectively delivered into HIV-1-infected macrophages using pH-sensitive liposomes. pH-sensitive liposomes with serum stability are being developed as in vivo delivery vehicles. Liposomes encapsulating an HIV-1 protease inhibitor were more effective in inhibiting virus production in infected macrophages than the free drug. Anionic liposomes were found to inhibit HIV-1 infectivity, while cationic liposomes had a differential toxicity for HIV-1-infected macrophages. Lipophilic sulfated cyclodextrins have been synthesized as novel antiviral agents. Liposome-encapsulated ciprofloxacin treatment reduced the number of viable M. avium in macrophages more than the free antibiotic. Liposome-encapsulated paromomycin and sparfloxacin were effective against M. tuberculosis inside macrophages, including multi-drug-resistant strains. Streptomycin encapsulated in liposomes and delivered intravenously or subcutaneously reduced the number of viable M. tuberculosis in infected mice and prevented mortality.Keywords
This publication has 63 references indexed in Scilit:
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.Proceedings of the National Academy of Sciences, 1993
- Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future [published erratum appears in Blood 1991 Dec 15;78(12):3330]Blood, 1991
- Targeted therapy of human immunodeficiency virus‐related diseaseThe FASEB Journal, 1991
- Mycobacterium aviumComplex Infection in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Antiviral Therapy of HIV InfectionAnnual Review of Medicine, 1991
- Fusion of simian immunodeficiency virus with liposomes and erythrocyte ghost membranes: effects of lipid composition, pH and calciumJournal of General Virology, 1990
- Mycobacterial Infections in. AIDS Patients, with an Emphasis on the Mycobacterium avium ComplexClinical Infectious Diseases, 1986
- Disease Due to Mycobacterium avium-intracellulareChest, 1985